RU2019101864A - Фармацевтическая композиция для лечения недержания мочи и способ ее применения - Google Patents
Фармацевтическая композиция для лечения недержания мочи и способ ее применения Download PDFInfo
- Publication number
- RU2019101864A RU2019101864A RU2019101864A RU2019101864A RU2019101864A RU 2019101864 A RU2019101864 A RU 2019101864A RU 2019101864 A RU2019101864 A RU 2019101864A RU 2019101864 A RU2019101864 A RU 2019101864A RU 2019101864 A RU2019101864 A RU 2019101864A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- acetaminophen
- amount
- specified
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Применение фармацевтической композиции для лечения ночного недержания мочи у ребенка, где указанная фармацевтическая композиция содержит множество активных ингредиентов, выбранных из группы состоящей из
ацетаминофена, и
ингибиторов фосфодиэстеразы 5 типа (ингибитор ФДЭ-5) и
где указанная фармацевтическая композиция составлена для немедленного высвобождения, замедленного высвобождения, отсроченного высвобождения или их комбинаций.
2. Применение по п.1, где указанная фармацевтическая композиция дополнительно покрыта кишечнорастворимой оболочкой.
3. Применение по п. 1, где указанная фармацевтическая композиция включает ацетаминофен в количестве 1-1000 мг.
4. Применение по п.1, где указанная фармацевтическая композиция включает ацетаминофен в количестве 10-300 мг.
5. Применение по п.1, где указанная фармацевтическая композиция включает ацетаминофен в количестве 300-1000 мг.
6. Фармацевтическая композиция для лечения ночного недержания мочи у ребенка, содержащая множество активных ингредиентов, выбранных из группы состоящей из
ацетаминофена, и
ингибиторов фосфодиэстеразы 5 типа (ингибитор ФДЭ-5), и
фармацевтически приемлемого носителя,
где указанная фармацевтическая композиция составлена для немедленного высвобождения, замедленного высвобождения, отсроченного высвобождения или их комбинаций.
7. Фармацевтическая композиция по п.6, где указанная фармацевтическая композиция дополнительно покрыта кишечнорастворимой оболочкой.
8. Фармацевтическая композиция по п. 6, где указанная фармацевтическая композиция включает ацетаминофен в количестве 1-1000 мг.
9. Фармацевтическая композиция по п.6, где указанная фармацевтическая композиция включает ацетаминофен в количестве 10-300 мг.
10. Фармацевтическая композиция по п.6, где указанная фармацевтическая композиция включает ацетаминофен в количестве 300-1000 мг.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/560,665 US8445011B2 (en) | 2010-07-08 | 2012-07-27 | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| US13/560,665 | 2012-07-27 | ||
| US13/800,761 US20130196012A1 (en) | 2010-11-30 | 2013-03-13 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US13/800,761 | 2013-03-13 | ||
| US13/847,940 | 2013-03-20 | ||
| US13/847,940 US8703184B2 (en) | 2010-07-08 | 2013-03-20 | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015106762A Division RU2015106762A (ru) | 2012-07-27 | 2013-06-28 | Фармацевтическая композиция для лечения недержания мочи и способ ее применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019101864A true RU2019101864A (ru) | 2019-03-11 |
Family
ID=49997724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015106762A RU2015106762A (ru) | 2012-07-27 | 2013-06-28 | Фармацевтическая композиция для лечения недержания мочи и способ ее применения |
| RU2015106672A RU2015106672A (ru) | 2012-07-27 | 2013-06-28 | Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения |
| RU2019101864A RU2019101864A (ru) | 2012-07-27 | 2013-06-28 | Фармацевтическая композиция для лечения недержания мочи и способ ее применения |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015106762A RU2015106762A (ru) | 2012-07-27 | 2013-06-28 | Фармацевтическая композиция для лечения недержания мочи и способ ее применения |
| RU2015106672A RU2015106672A (ru) | 2012-07-27 | 2013-06-28 | Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20160022615A1 (ru) |
| EP (3) | EP2844241A4 (ru) |
| JP (4) | JP2015522658A (ru) |
| KR (2) | KR20150048741A (ru) |
| CN (4) | CN107335057A (ru) |
| AU (3) | AU2013293489B2 (ru) |
| BR (2) | BR112014031306A2 (ru) |
| CA (2) | CA2879640A1 (ru) |
| HK (4) | HK1205932A1 (ru) |
| IL (3) | IL236028A0 (ru) |
| MX (2) | MX2015001188A (ru) |
| MY (1) | MY171526A (ru) |
| RU (3) | RU2015106762A (ru) |
| SG (2) | SG11201500601QA (ru) |
| WO (2) | WO2014018222A1 (ru) |
| ZA (2) | ZA201408993B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370144B2 (en) | 2021-02-23 | 2025-07-29 | Otsuka Pharmaceutical Co., Ltd. | Centanafadine pharmaceutical formulations, and methods of making and using same |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017039832A1 (en) * | 2015-09-01 | 2017-03-09 | Wellesley Pharmaceuticals, Llc | Extended, delayed and immediate release formulation method of manufacturing and use thereof |
| WO2017058436A1 (en) * | 2015-09-30 | 2017-04-06 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| AU2016331871A1 (en) * | 2015-09-30 | 2018-05-17 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
| TW201726114A (zh) * | 2015-11-23 | 2017-08-01 | 魏斯理製藥公司 | 降低排尿頻率之組成物、其製備方法、及其應用 |
| WO2019094989A1 (en) * | 2017-11-07 | 2019-05-16 | Poviva Tea, Llc | Food and beverage compositions comprising pde5 inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL143846A0 (en) * | 1998-12-23 | 2002-04-21 | Alza Corp | Dosage forms comprising porous particles |
| AU7360700A (en) * | 1999-09-09 | 2001-04-10 | Androsolutions, Inc. | Methods and compositions for preventing and treating urinary tract disorders |
| EP1313478A2 (en) * | 2000-08-30 | 2003-05-28 | Lilly Icos LLC | Method for treatment of migraine using pde5 inhibitors |
| WO2003029199A1 (en) * | 2001-09-28 | 2003-04-10 | Takeda Chemical Industries, Ltd. | Benzene derivatives, process for preparing the same and use thereof |
| JP2005526040A (ja) * | 2002-02-19 | 2005-09-02 | ファルマシア・コーポレーション | 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用 |
| WO2004043365A2 (en) * | 2002-11-06 | 2004-05-27 | Azaya Therapeutics, Inc. | Method for treatment of premature ejaculation in humans |
| EP1879578A4 (en) * | 2005-03-21 | 2009-05-13 | Dov Pharmaceutical Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE |
| EP1741444A1 (en) * | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| US20080166407A1 (en) * | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| WO2007083323A2 (en) * | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
| WO2007113243A2 (en) * | 2006-03-31 | 2007-10-11 | Investigación Y Clínica Andrológicas S.L. | Use of pde 5 inhibitors for the treatment of overactive bladder |
| CA2695634C (en) * | 2007-08-06 | 2018-01-23 | Serenity Pharmaceuticals Corporation | Methods and devices for desmopressin drug delivery |
| CN101664555A (zh) * | 2008-09-02 | 2010-03-10 | 许洁 | 用于治疗泌尿生殖系统感染性疾病的联合药物组合物 |
| CN102028693A (zh) * | 2009-09-30 | 2011-04-27 | 梁超峰 | 含有5-型磷酸二酯酶抑制剂的直肠给药组合物 |
| US9260424B2 (en) * | 2009-10-26 | 2016-02-16 | Auspex Pharmaceuticals, Inc. | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
| US20120141554A1 (en) * | 2010-07-08 | 2012-06-07 | Wellesley Pharmaceuticals, Llc | Delayed release formulation for reducing the frequency of urination and method of use thereof |
| US8236856B2 (en) * | 2010-07-08 | 2012-08-07 | Wellesley Pharmaceuticals, Llc | Delayed release formulation for reducing the frequency of urination and method of use thereof |
| US8236857B2 (en) * | 2010-07-08 | 2012-08-07 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US20120244221A1 (en) * | 2010-07-08 | 2012-09-27 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US20120135050A1 (en) * | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US20120010294A1 (en) * | 2010-07-08 | 2012-01-12 | Dill David A | Compositions and methods for the inhibition of muscle contraction |
-
2013
- 2013-06-28 WO PCT/US2013/048616 patent/WO2014018222A1/en not_active Ceased
- 2013-06-28 KR KR1020157005105A patent/KR20150048741A/ko not_active Ceased
- 2013-06-28 HK HK15106440.6A patent/HK1205932A1/xx unknown
- 2013-06-28 EP EP13823428.1A patent/EP2844241A4/en not_active Ceased
- 2013-06-28 CA CA2879640A patent/CA2879640A1/en not_active Abandoned
- 2013-06-28 CN CN201710662273.6A patent/CN107335057A/zh active Pending
- 2013-06-28 BR BR112014031306A patent/BR112014031306A2/pt not_active Application Discontinuation
- 2013-06-28 MX MX2015001188A patent/MX2015001188A/es unknown
- 2013-06-28 RU RU2015106762A patent/RU2015106762A/ru unknown
- 2013-06-28 EP EP19153805.7A patent/EP3527204A1/en not_active Withdrawn
- 2013-06-28 RU RU2015106672A patent/RU2015106672A/ru unknown
- 2013-06-28 MX MX2015001190A patent/MX2015001190A/es unknown
- 2013-06-28 MY MYPI2015700161A patent/MY171526A/en unknown
- 2013-06-28 WO PCT/US2013/048627 patent/WO2014018223A1/en not_active Ceased
- 2013-06-28 BR BR112015001627A patent/BR112015001627A2/pt not_active Application Discontinuation
- 2013-06-28 RU RU2019101864A patent/RU2019101864A/ru not_active Application Discontinuation
- 2013-06-28 SG SG11201500601QA patent/SG11201500601QA/en unknown
- 2013-06-28 JP JP2015524291A patent/JP2015522658A/ja active Pending
- 2013-06-28 CN CN201711139409.1A patent/CN107661326A/zh active Pending
- 2013-06-28 JP JP2015524292A patent/JP2015522659A/ja active Pending
- 2013-06-28 CA CA2875818A patent/CA2875818A1/en not_active Abandoned
- 2013-06-28 EP EP13822479.5A patent/EP2877179A4/en not_active Ceased
- 2013-06-28 AU AU2013293489A patent/AU2013293489B2/en not_active Ceased
- 2013-06-28 CN CN201380038506.5A patent/CN104470522A/zh active Pending
- 2013-06-28 SG SG11201500578VA patent/SG11201500578VA/en unknown
- 2013-06-28 KR KR1020157005100A patent/KR20150048740A/ko not_active Ceased
- 2013-06-28 AU AU2013293488A patent/AU2013293488B2/en not_active Ceased
- 2013-06-28 CN CN201380037454.XA patent/CN104540505A/zh active Pending
- 2013-06-28 HK HK15106439.9A patent/HK1205931A1/xx unknown
-
2014
- 2014-12-02 IL IL236028A patent/IL236028A0/en unknown
- 2014-12-08 ZA ZA2014/08993A patent/ZA201408993B/en unknown
-
2015
- 2015-01-11 IL IL236622A patent/IL236622A0/en not_active IP Right Cessation
- 2015-01-22 ZA ZA2015/00459A patent/ZA201500459B/en unknown
- 2015-07-06 HK HK18110004.3A patent/HK1250628A1/zh unknown
- 2015-07-06 HK HK18105893.7A patent/HK1246203A1/zh unknown
- 2015-10-02 US US14/873,919 patent/US20160022615A1/en not_active Abandoned
-
2016
- 2016-11-03 US US15/342,783 patent/US20170100351A1/en not_active Abandoned
-
2017
- 2017-10-24 JP JP2017204851A patent/JP2018039831A/ja active Pending
-
2018
- 2018-04-16 JP JP2018078173A patent/JP2018127482A/ja active Pending
- 2018-07-30 AU AU2018208765A patent/AU2018208765A1/en not_active Abandoned
- 2018-08-08 US US16/058,096 patent/US20180344674A1/en not_active Abandoned
- 2018-08-19 IL IL261232A patent/IL261232A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370144B2 (en) | 2021-02-23 | 2025-07-29 | Otsuka Pharmaceutical Co., Ltd. | Centanafadine pharmaceutical formulations, and methods of making and using same |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019101864A (ru) | Фармацевтическая композиция для лечения недержания мочи и способ ее применения | |
| EA201790950A1 (ru) | Способы и композиции, в частности, для лечения синдрома дефицита внимания | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| CL2007002867A1 (es) | Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras. | |
| CR10455A (es) | Compuestos farmaceuticos | |
| MX2012003555A (es) | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. | |
| UA106457C2 (ru) | Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы | |
| IN2012DN01869A (ru) | ||
| EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
| WO2013001372A3 (en) | Methods and compositions for inhibition of activation of regulatory t cells | |
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| WO2010033977A3 (en) | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| PH12018500023A1 (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| WO2011133795A3 (en) | Beta-carbolines as inhibitors of haspin and dyrk kinases | |
| EP2629799A4 (en) | TOPICAL BASE AND ACTIVE COMPOSITIONS AND PROCESS FOR THE CARE AND TREATMENT OF THE SKIN | |
| JP2013536238A5 (ru) | ||
| WO2011149288A2 (ko) | 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물 | |
| WO2008075231A3 (en) | Diaper rash composition and method | |
| MX351059B (es) | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. | |
| UY29193A1 (es) | Nuevas formulaciones de tabletas de liberación modificada para inhibidores de bomba de protón | |
| NZ714662A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| RU2016152226A (ru) | Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения | |
| JP2015522659A5 (ru) | ||
| EA201390354A1 (ru) | Хиноксалиновое соединение | |
| GEP201706743B (en) | Oral formulation for the treatment of cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160629 |